Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Eligibility Bill May Carve Out Patenting Of Research

Executive Summary

Witnesses at US Senate hearings debate bill's impact on drug pricing; discuss limiting it to medical diagnostics.

You may also be interested in...



Patent Office To Drop Some Proposed Revisions To Patent Challenge Proceedings, Vidal Tells Congress

Not all PTAB changes floated in advanced notice of proposed rulemaking will be pursued, and the rule may be split into two, USPTO Director Vidal testifies. Industry groups criticize the proposals.

Patent Office To Drop Some Proposed Revisions To Patent Challenge Proceedings, Vidal Tells Congress

Not all PTAB changes floated in advanced notice of proposed rulemaking will be pursued, and the rule may be split into two, USPTO Director Vidal testifies. PhRMA, BIO, AAM criticize the proposals.

Biopharma Dismayed US Supreme Court Declines To Take Up Case On Patent Eligibility

The Court denies a petition for review of American Axle and Manufacturing v. Neapco despite requests from the US government, BIO and former PTO director Kappos that it take up the case to  provide greater clarity on the types of inventions that may be patented.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel